Intellia Therapeutics (NTLA) reported Q3 earnings on Thur 6 Nov 25 (a/h)

Intellia Therapeutics announced third quarter 2025 financial results and provided updates on its MAGNITUDE and MAGNITUDE-2 Phase 3 trials, including the recent patient death and ongoing FDA clinical hold, with a conference call scheduled for today at 6:00 p.m. ET.

 

** before earnings **

** after earnings **